HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shahzad G. Raja Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raja, S. G. Search for Related Content PubMed PubMed Citation Articles by Raja, S. G. Related Collections Cardiac - pharmacology Coronary disease

Eur J Cardiothorac Surg 2004;26:231
© 2004 Elsevier Science NL

Letter to the Editor

Clopidogrel before coronary artery surgery: bleeding or no bleeding?

Department of Cardiac Surgery, Royal Liverpool Children's NHS Trust, Alder Hey Hospital, Eaton Road, Liverpool L12 2AP, UK

Received 15 March 2004; accepted 13 April 2004.

^* Tel.: +44-151-252-5643; fax: +44-151-252-5635
e-mail: drrajashahzad{at}hotmail.com

Key Words: Clopidogrel • Coronary artery bypass surgery • Platelet aggregation inhibitors • Bleeding

The recent article by Karabulut et al. [1] on use of clopidogrel before coronary artery surgery addresses an important issue faced by most cardiac surgeons in the modern era of acute coronary syndrome (ACS) and percutaneous interventions. The results of this prospective observational study suggest that preoperative use of clopidogrel is not associated with increased bleeding and need for surgical exploration as well as risk of blood and blood product transfusion after CABG. Interestingly, these results are not only contrary to those of the other researchers [2–4] but also contradict the expected effect of clopidogrel administration [5].

Clopidogrel, a thienopyridine derivative, is an antiplatelet agent that inhibits the P2Y₁₂ receptor and is used as an antithrombotic drug [5]. It produces irreversible inhibition of platelet aggregation, and therefore the effect is present for the life of the platelet. Bleeding time returns to normal 10 days after ceasing clopidogrel administration [5]. Based on this information, for elective surgical procedures, clopidogrel should be stopped 7–10 days before surgery, except if the benefit of the antiplatelet effect outweighs the risk of perioperative bleeding. However, with the latest boom in percutaneous intervention techniques, cardiologists prefer clopidogrel treatment in addition to aspirin before percutaneous coronary intervention. This regime has been shown to decrease the incidence of coronary occlusive events [5].

A sequel of this protocol is the changing profile of coronary artery surgery patients. Today a significant number of patients presenting with ACS may be sent directly for coronary artery surgery from the catheterization suite owing to one reason or another. As these patients have been on clopidogrel and other anticoagulation medication, the potential risk of increased postoperative bleeding and need for re-exploration and transfusion of blood products raises concerns about preoperative use of clopidogrel.

Although, the study of Karabulut et al. [1] down plays the impact of clopidogrel on postoperative bleeding, in actual practice, the haemostatic derangements associated with cardiopulmonary bypass present a significant concern for patients undergoing emergency coronary artery surgery after acute loading with clopidogrel. Irrespective of whether preoperative clopidogrel administration results in bleeding or no bleeding, it is extremely important to realize that there is a window of opportunity to perform urgent bypass grafting. This arises from the delay in the formation of the active metabolite of clopidogrel. The inhibition of platelet aggregation by clopidogrel commences within 1 h of a 375 mg loading dose and reaches its peak effect at 5 h [5]. Hence, full advantage should be taken of this information. In addition, avoiding cardiopulmonary bypass and performing myocardial revascularization ‘off-pump’ in patients who have received clopidogrel may theoretically reduce the incidence of postoperative bleeding. Aprotinin and desmopressin may also reduce postoperative bleeding after clopidogrel administration although concrete evidence is lacking [5]. However, in the case of active, uncontrolled bleeding, it is extremely important to remember that platelet transfusion is the only effective treatment.

References

1. Karabulut H., Toraman F., Evrenkaya S., Goksel O., Tarcan S., Alhan C. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004;25:419-423.[Abstract/Free Full Text]
2. Pothula S., Sanchala V.T., Nagappala B., Inchiosa M.A., Jr The effect of preoperative antiplatelet/anticoagulant prophylaxis on postoperative blood loss in cardiac surgery. Anesth Analg 2004;98:4-10.[Abstract/Free Full Text]
3. Hongo R.H., Ley J., Dick S.E., Yee R.R. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40:231-237.[Abstract/Free Full Text]
4. Yende S., Wunderink R.G. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med 2001;29:2271-2275.[CrossRef][Medline]
5. Kam P.C., Nethery C.M. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003;58:28-35.[CrossRef][Medline]

This article has been cited by other articles:

				S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Shahzad G. Raja Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Raja, S. G. Search for Related Content PubMed PubMed Citation Articles by Raja, S. G. Related Collections Cardiac - pharmacology Coronary disease